Luckily, you can check this free report showing analyst forecasts for its future. If you are like me, you may want to think about whether this company will grow or shrink. Be aware that Endo International is showing 3 warning signs in our investment analysis, and 1 of those is a bit concerning. But to truly gain insight, we need to consider other information, too. I find it very interesting to look at who exactly owns a company. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. The general public, who are usually individual investors, hold a 17% stake in Endo International. You can click here to see if those insiders have been buying or selling. Many investors in smaller companies prefer to see the board more heavily invested. It seems the board members have no more than US$998k worth of shares in the US$123m company. Our information suggests that Endo International plc insiders own under 1% of the company. This can be negative in some circumstances. ![]() However, high insider ownership can also give immense power to a small group within the company. ![]() Insider ownership is positive when it signals leadership are thinking like the true owners of the company. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Our data reflects individual insiders, capturing board members at the very least. In June, the drugmaker missed a $38 million interest payment, amid discussions with a group of unsecured bondholders who had urged the company to avoid filing for bankruptcy.The definition of company insiders can be subjective and does vary between jurisdictions. state attorneys general to provide $450 million over a period of 10 years, resolving allegations that the company boosted opioid sales using deceptive marketing, and bans the marketing of its opioids forever, according to the office of Massachusetts AG.Ĭreditors will also establish voluntary trusts with $550 million to be funded over 10 years to settle the opioid claims, the company said.Įndo has been discussing the possibility of filing for bankruptcy protection in several recent filings. The company also reached a deal with U.S. ![]() The creditors, who will also assume some of the company's liabilities, will substantially control all of its assets, Endo said. The company's Chapter 11 bankruptcy filing in the Southern District of New York showed assets and liabilities in the range of $1 billion to $10 billion. "By definitively addressing the more than $8 billion of debt that has burdened our balance sheet and establishing a pathway to closure with respect to the thousands of opioid-related and other lawsuits that the company has been defending at an unsustainable cost, we will be able to move forward.," Endo's Chief Executive Officer Blaise Coleman said in a statement. Purdue Pharma, the maker of Ox圜ontin, filed in September 2019, while Mallinckrodt Plc, a generic opioid manufacturer, recently emerged from bankruptcy. The pharmaceutical company is the latest to file for Chapter 11 to address opioid claims. drugmaker seeks to settle thousands of lawsuits over its alleged role in the country's opioid epidemic. Aug 16 (Reuters) - Endo International Plc (ENDP.O) filed for bankruptcy on Tuesday after reaching a $6 billion deal with some of its creditors, as the U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |